$9.05
1.95% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
NL0015285941
Symbol
IMTX

Immatics N.V Stock price

$9.05
-0.36 3.83% 1M
+4.66 106.15% 6M
+1.94 27.29% YTD
-0.20 2.16% 1Y
-1.39 13.31% 3Y
-0.85 8.59% 5Y
-0.55 5.73% 10Y
-0.55 5.73% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.18 1.95%
ISIN
NL0015285941
Symbol
IMTX
Industry

New AI Insights on Immatics N.V Insights AI Insights on Immatics N.V

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$589.5m
Net debt
positive
Cash
$553.2m
Shares outstanding
121.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.5 | 21.5
EV/Sales
3.9 | 11.3
EV/FCF
negative
P/B
2.1
Financial Health
Equity Ratio
82.6%
Return on Equity
2.7%
ROCE
-17.1%
ROIC
-239.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$150.6m | $52.2m
EBITDA
$-86.6m | $-194.1m
EBIT
$-100.8m | $-217.1m
Net Income
$-85.5m | $-222.5m
Free Cash Flow
$-202.1m
Growth (TTM | estimate)
Revenue
83.6% | -71.0%
EBITDA
18.1% | -464.0%
EBIT
13.8% | -386.9%
Net Income
-0.3% | -1,366.1%
Free Cash Flow
-288.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-57.5% | -372.2%
EBIT
-66.9%
Net
-56.8% | -426.5%
Free Cash Flow
-134.3%
More
EPS
$-0.7
FCF per Share
$-1.7
Short interest
4.6%
Employees
646
Rev per Employee
$280.0k
Show more

Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Immatics N.V Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Immatics N.V forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Immatics N.V forecast:

Buy
94%
Hold
6%

Financial data from Immatics N.V

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
151 151
84% 84%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 57 57
21% 21%
38%
- Research and Development Expense 194 194
28% 28%
129%
-87 -87
18% 18%
-57%
- Depreciation and Amortization 14 14
27% 27%
9%
EBIT (Operating Income) EBIT -101 -101
14% 14%
-67%
Net Profit -86 -86
0% 0%
-57%

In millions USD.

Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immatics N.V Stock News

Neutral
GlobeNewsWire
12 days ago
Houston , Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, lea...
Neutral
GlobeNewsWire
19 days ago
Houston , Texas and Tuebingen, Germany, October 20, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the presentation of updated data from 16 patients with metastatic uveal melanoma treated with anzu-cel PRAME cell therapy.
Positive
Seeking Alpha
29 days ago
IMTX is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Anzu-cel offers advantages over IOVA's Amtagvi, including less invasive cell collection, faster turnaround, and no need for high-dose IL-2. Phase 1b data show a 56% objective response rate and 91% disease control rate in melanoma patients treated with IMTX's therapy.
More Immatics N.V News

Company Profile

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Head office Netherlands
CEO Harpreet Singh-Jasuja
Employees 646
Founded 2020
Website immatics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today